FGFR4 and breast cancer: Indeed, inhibition of FGFR4/FGF19 autocrine signaling synergizes with doxorubicin (but not cisplatin or paclitaxel) to enhance sensitivity in basal-like breast cancer cells, highlighting the potential of using an anti-FGF19 monoclonal antibody as a therapeutic for breast cancer cells that co-express FGFR4 and FGF19.